JAGX - Jaguar Health, Inc.
5.045
0.325 6.442%
Share volume: 27,473
Last Updated: 04-09-2025
Pharmaceutical Products/Pharmaceutical Preparations:
0.07%
PREVIOUS CLOSE
CHG
CHG%
$4.72
0.33
0.07%
Fundamental analysis
29%
Profitability
8%
Dept financing
24%
Liquidity
75%
Performance
40%
Performance
5 Days
5.32%
1 Month
822.98%
3 Months
404.50%
6 Months
300.40%
1 Year
4,249.14%
2 Year
834.43%
Key data
Stock price
$5.04
DAY RANGE
$4.51 - $5.14
52 WEEK RANGE
$0.09 - $7.25
52 WEEK CHANGE
$4,593.02
DIVIDEND
$0.00
EX-DIVIDEND DATE
03-24-2025
NEXT EARNINGS DATE
05-13-2025
Company detail
CEO: Lisa A. Conte
Region: US
Website: jaguar.health
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: jaguar.health
Employees: 50
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Jaguar Health, Inc. focuses on developing prescription medicines for people and animals with gastrointestinal distress. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera.
Recent news
